Figure 1.
Response in 1 patient who achieved a partial response to ibrutinib therapy with SS/MF and CLL. (A) Ibrutinib therapy resulted in significant decrease in both abnormal (Abn) B-cell (CLL) and Abn T-cell (Sezary) populations. (B) The patient’s Sezary population at baseline was 2370 cells/mm3; after ibrutinib therapy, his Sezary population has ranged from 803 to 2000 cells/mm3, most recently being 1325 cells/mm3. He had a marked rise in white blood cell count in the setting of acute appendicitis in December 2015. Ibrutinib was held for 84 days during appendicitis treatment (antibiotics and surgery) and recovery. Ibrutinib was restarted March 2016, and the patient has continued on therapy to date.
